Q32 Bio (QTTB) Total Liabilities (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Total Liabilities of $17.4 million for Q1 2026, down 79.1% year-over-year from $83.1 million in Q1 2025, and down 12.14% quarter-over-quarter from $19.8 million in Q4 2025.
Q32 Bio (QTTB) Total Liabilities (2017 - 2026) Analysis & Trends
Q32 Bio's Total Liabilities history runs 10 years deep, the most recent figure standing at $17.4 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 79.1% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $17.4 million (down 79.1% YoY), while the FY2025 annual figure was $19.8 million, down 77.2% from the prior year.
- Total Liabilities for Q1 2026 stood at $17.4 million, down from $19.8 million in the prior quarter.
- The five-year high for Total Liabilities was $118.5 million in Q4 2023, with the low at $17.4 million in Q1 2026.
- The 5-year median for Total Liabilities is $53.6 million (2022), against an average of $64.8 million.
- The sharpest annual moves came in 2023 and 2026: Total Liabilities surged 134.76% in 2023, then slumped 79.1% in 2026.
- Q32 Bio's Total Liabilities stood at $50.5 million in 2022, then soared by 134.76% to $118.5 million in 2023, then decreased by 26.89% to $86.7 million in 2024, then tumbled by 77.2% to $19.8 million in 2025, then fell by 12.14% to $17.4 million in 2026.
- Business Quant data shows QTTB's Total Liabilities at $17.4 million in Q1 2026, $19.8 million in Q4 2025, and $76.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 9.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.96 Mn |
| Mar 31, 2026 | 17.36 Mn |
| Dec 31, 2025 | 19.76 Mn |
| Sep 30, 2025 | 76.23 Mn |
| Jun 30, 2025 | 78.35 Mn |
| Mar 31, 2025 | 83.09 Mn |
| Dec 31, 2024 | 86.66 Mn |
| Sep 30, 2024 | 86.25 Mn |
| Jun 30, 2024 | 90.70 Mn |
| Mar 31, 2024 | 103.57 Mn |
| Dec 31, 2023 | 118.53 Mn |
| Sep 30, 2023 | 51.85 Mn |
| Jun 30, 2023 | 49.96 Mn |
| Mar 31, 2023 | 45.98 Mn |
| Dec 31, 2022 | 50.49 Mn |
| Sep 30, 2022 | 53.59 Mn |
| Jun 30, 2022 | 44.32 Mn |
| Mar 31, 2022 | 44.70 Mn |
| Dec 31, 2021 | 42.07 Mn |
| Sep 30, 2021 | 32.25 Mn |